Precigen (PGEN) Expected to Post Earnings on Wednesday

Precigen (NASDAQ:PGEN) will likely be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.0589 per share and revenue of $71.56 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. The business had revenue of $54.98 million for the quarter, compared to the consensus estimate of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The business’s quarterly revenue was up 6322.7% on a year-over-year basis. On average, analysts expect Precigen to post $0.23 EPS for the current fiscal year and $0.72 EPS for the next fiscal year.

Precigen Stock Down 26.0%

Precigen stock traded down $1.80 during midday trading on Monday, hitting $5.14. 4,272,484 shares of the company were exchanged, compared to its average volume of 4,714,712. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen has a fifty-two week low of $3.04 and a fifty-two week high of $8.98. The company’s fifty day moving average price is $7.22 and its 200-day moving average price is $5.27. The company has a market cap of $1.83 billion, a PE ratio of -4.88 and a beta of 1.01.

Analysts Set New Price Targets

PGEN has been the topic of a number of recent research reports. B. Riley Financial began coverage on shares of Precigen in a research report on Friday, September 25th. They issued a “buy” rating and a $12.00 price target on the stock. Zacks Research cut Precigen from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. HC Wainwright raised their target price on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen cut shares of Precigen from a “strong-buy” rating to a “buy” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.67.

Insider Buying and Selling at Precigen

In other Precigen news, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director directly owned 17,100 shares in the company, valued at approximately $127,224. This trade represents a 91.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Rutul R. Shah sold 15,342 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the transaction, the chief operating officer owned 468,865 shares in the company, valued at $3,516,487.50. This represents a 3.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 267,739 shares of company stock valued at $1,975,990. Corporate insiders own 41.40% of the company’s stock.

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.